6-(isoquinolin-5-yl)-N,N-dimethyl-5-(pyridin-4-yl)pyridazin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-(isoquinolin-5-yl)-N,N-dimethyl-5-(pyridin-4-yl)pyridazin-3-amine
• 英文别名: MW-12-082；MW01-12-082SRM；MW082；6-isoquinolin-5-yl-N,N-dimethyl-5-pyridin-4-ylpyridazin-3-amine
• 化学式: C₂₀H₁₇N₅
• 分子量: 327.388
• InChiKey: HVUMELUATKNGAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• MAP KINASE MODULATORS AND USES THEREOF
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20160130253A1

  公开（公告）日：2016-05-12

  The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38α MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

  本发明提供了新型的MAP激酶抑制剂和包含它们的组合物。在某些实施例中，MAP激酶抑制剂是p38α MAP激酶抑制剂。该发明还提供了治疗疾病的方法，包括给予MAP激酶抑制剂或包含MAP激酶抑制剂的组合物。在某些实施例中，该疾病是阿尔茨海默病，肌萎缩性侧索硬化症，亨廷顿病或帕金森病。
• PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP3521284A1

  公开（公告）日：2019-08-07

  The invention provides novel MAP kinase inhibitors of formula (I) and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38a MAP kinase inhibitors. The invention further provides compounds (I) for use in the methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease. wherein X1 is CH and X2 is N.

  本发明提供了式(I)的新型MAP激酶抑制剂和包含其的组合物。在某些实施方案中，MAP 激酶抑制剂是 p38a MAP 激酶抑制剂。本发明进一步提供了化合物(I)用于治疗疾病的方法，包括施用MAP激酶抑制剂或包含MAP激酶抑制剂的组合物。在某些实施方案中，疾病是阿尔茨海默病、渐冻人症、亨廷顿氏病或帕金森氏病。 其中X1为CH，X2为N。
• MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP3842424A1

  公开（公告）日：2021-06-30

  The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38a MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

  本发明提供了新型 MAP 激酶抑制剂和包含这些抑制剂的组合物。在某些实施方案中，MAP 激酶抑制剂是 p38a MAP 激酶抑制剂。本发明进一步提供了治疗疾病的方法，包括给予 MAP 激酶抑制剂或包含 MAP 激酶抑制剂的组合物。在一些实施方案中，疾病是阿尔茨海默病、渐冻人症、亨廷顿氏病或帕金森氏病。
• MAP kinase modulators and uses thereof
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10428047B2

  公开（公告）日：2019-10-01

  The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38α MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.

  本发明提供了新型 MAP 激酶抑制剂和包含这些抑制剂的组合物。在某些实施方案中，MAP 激酶抑制剂是 p38α MAP 激酶抑制剂。本发明进一步提供了治疗疾病的方法，包括施用 MAP 激酶抑制剂或包含 MAP 激酶抑制剂的组合物。在某些实施方案中，疾病是阿尔茨海默病、渐冻人症、亨廷顿氏病或帕金森氏病。
• Compositions and Methods for Treating Autism Spectrum Disorders
  申请人：Vanderbilt University

  公开号：US20160151366A1

  公开（公告）日：2016-06-02

  Methods and compositions for use in treating autism spectrum disorder (ASD) include use of specific CNS penetrant p38α MAPK inhibitors having the structure of formula (I)